i-FACTOR®
-
Biologics
Cerapedics Reinforces Commitment to Level 1 Evidence with Long-Term Results from Six-Year Pivotal IDE Cervical Study Demonstrating 98.6% Spine Fusion Rates in Patients Treated With i-FACTOR®
WESTMINSTER, Colo., Oct. 17, 2023 /PRNewswire/ — Cerapedics Inc., a commercial-stage orthopedics company dedicated to redefining the standard of care for bone…
Read More » -
Biologics
Cerapedics Announces Commercial Launch of i-FACTOR®+ Matrix in Canada
Canada will be the first commercial market to launch i-FACTOR®+ Matrix WESTMINSTER, Colo., Nov. 5, 2020 /PRNewswire/ — Cerapedics, a private ortho-biologics company, today…
Read More » -
Biologics
Cerapedics Announces Results from Clinical Trial of i-FACTOR® Peptide Enhanced Bone Graft in Lumbar Fusion Surgery
WESTMINSTER, Colo., May 19, 2020 /PRNewswire/ — Cerapedics, a private ortho-biologics company, today announced that results from a clinical trial evaluating i-FACTOR Peptide…
Read More »